Abstract Background and aims Inflammatory Bowel Disease (IBD) are chronic inflammatory conditions of the gastrointestinal tract with increasing prevalence. Current therapies are only partially efficient and associated with potentially severe side effects. New therapeutic strategies with innovative targets are thus urgently needed. Neutrophils are key players of innate immunity in IBD, but their roles in disease development are neglected compared to those of other immune cells. Essential to host defence, their overactivation can cause chronic inflammation and tissue damage. Converging evidence has highlighted interactions between neutrophils, gut inflammation and microbiota. Notably, numerous IBD susceptibility genes are involved in neutrophil functions related to defence against microbes; and IBD is associated with alterations of the intestinal microbiota. However, the influence of microbiota on neutrophil functions, and the consequences in terms of disease development remain largely unknown. Microbiota metabolites, including short-chain fatty acids, bile acids, and tryptophan (Trp)-derived metabolites, have shown regulatory effects on immune cell types, such as T cells and macrophages. However, their impact on neutrophils is underexplored, especially concerning indole derivatives, molecules derived from Trp degradation by the microbiota. Based on preliminary data, our objectives are to (i) explore the influence of two indole derivatives, indole and indoxyl-3-sulfate (I3S), on neutrophil functions in homeostasis, and (ii) decipher the effect of these microbiota metabolites on neutrophils in the context of intestinal inflammation. Methods Our project follows systematic approaches and takes advantage of up-to-date technologies (flow cytometry and Seahorse) and access to unique mouse and human samples (blood and intestinal tissue from the Saint-Antoine Hospital). Anticipated impact Based on both basic and translational research, it is essential to better understand the roles played by neutrophils in host-microbiota interactions in homeostasis and intestinal inflammation and to identify new therapeutic targets for IBD patients.